➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

ADENOSINE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Adenosine patents expire, and when can generic versions of Adenosine launch?

Adenosine is a drug marketed by Akorn, Am Regent, Fresenius Kabi Usa, Gland Pharma Ltd, Mylan Labs Ltd, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Aurobindo Pharma Ltd, Emcure Pharms Ltd, Hospira Inc, and Mylan Asi. and is included in twenty-one NDAs.

The generic ingredient in ADENOSINE is adenosine. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.

US ANDA Litigation and Generic Entry Outlook for Adenosine

A generic version of ADENOSINE was approved as adenosine by WEST-WARD PHARMS INT on June 16th, 2004.

  Start Trial

Drug patent expirations by year for ADENOSINE
Drug Prices for ADENOSINE

See drug prices for ADENOSINE

Recent Clinical Trials for ADENOSINE

Identify potential brand extensions & 505(b)(2) entrants

Alliance for Clinical Trials in OncologyPhase 3
University of Kansas Medical CenterPhase 2
University of IowaPhase 2

See all ADENOSINE clinical trials

Pharmacology for ADENOSINE
Medical Subject Heading (MeSH) Categories for ADENOSINE
Paragraph IV (Patent) Challenges for ADENOSINE
Tradename Dosage Ingredient NDA Submissiondate
ADENOSCAN SOLUTION;INTRAVENOUS adenosine 020059 2005-04-16

US Patents and Regulatory Information for ADENOSINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa ADENOSINE adenosine SOLUTION;INTRAVENOUS 077425-002 Aug 29, 2013 AP RX No Yes   Start Trial   Start Trial   Start Trial
Akorn ADENOSINE adenosine INJECTABLE;INJECTION 078076-001 Oct 31, 2008 AP RX No Yes   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd ADENOSINE adenosine SOLUTION;INTRAVENOUS 205331-002 Nov 2, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
Hospira Inc ADENOSINE adenosine SOLUTION;INTRAVENOUS 203883-002 Mar 24, 2014 AP RX No No   Start Trial   Start Trial   Start Trial
Mylan Labs Ltd ADENOSINE adenosine INJECTABLE;INJECTION 078640-001 Mar 21, 2014 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.